Northern Trust Corp lifted its stake in shares of USANA Health Sciences, Inc. (NYSE:USNA) by 10.5% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 177,630 shares of the company’s stock after purchasing an additional 16,948 shares during the period. Northern Trust Corp owned about 0.71% of USANA Health Sciences worth $11,386,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds also recently added to or reduced their stakes in the company. Old Mutual Global Investors UK Ltd. boosted its position in USANA Health Sciences by 29.7% during the second quarter. Old Mutual Global Investors UK Ltd. now owns 239,680 shares of the company’s stock worth $15,363,000 after acquiring an additional 54,831 shares during the last quarter. Schroder Investment Management Group boosted its holdings in USANA Health Sciences by 9.0% in the 2nd quarter. Schroder Investment Management Group now owns 572,186 shares of the company’s stock valued at $36,734,000 after purchasing an additional 47,448 shares during the last quarter. Vanguard Group Inc. boosted its holdings in USANA Health Sciences by 4.0% in the 1st quarter. Vanguard Group Inc. now owns 954,590 shares of the company’s stock valued at $54,984,000 after purchasing an additional 36,655 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in USANA Health Sciences by 107.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 56,373 shares of the company’s stock valued at $3,247,000 after purchasing an additional 29,162 shares during the last quarter. Finally, TIAA CREF Investment Management LLC boosted its holdings in USANA Health Sciences by 28.5% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 118,066 shares of the company’s stock valued at $7,568,000 after purchasing an additional 26,152 shares during the last quarter. 44.54% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by TrueBlueTribune and is owned by of TrueBlueTribune. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.truebluetribune.com/2017/11/14/northern-trust-corp-boosts-holdings-in-usana-health-sciences-inc-usna.html.
Several equities analysts have weighed in on the stock. BidaskClub lowered shares of USANA Health Sciences from a “hold” rating to a “sell” rating in a report on Thursday, November 2nd. Pivotal Research upped their price objective on shares of USANA Health Sciences from $70.00 to $80.00 and gave the stock a “buy” rating in a report on Wednesday, October 25th.
In other news, major shareholder Global Ltd Gull sold 60,871 shares of the firm’s stock in a transaction on Thursday, October 26th. The shares were sold at an average price of $67.39, for a total value of $4,102,096.69. Following the completion of the sale, the insider now owns 12,089,267 shares in the company, valued at approximately $814,695,703.13. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Myron W. Wentz sold 5,304 shares of the stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $66.01, for a total transaction of $350,117.04. Following the completion of the transaction, the director now owns 12,011,418 shares of the company’s stock, valued at approximately $792,873,702.18. The disclosure for this sale can be found here. Insiders sold a total of 557,067 shares of company stock worth $34,451,431 over the last ninety days. Insiders own 53.20% of the company’s stock.
Shares of USANA Health Sciences, Inc. (NYSE USNA) opened at $65.85 on Tuesday. USANA Health Sciences, Inc. has a 52 week low of $52.55 and a 52 week high of $71.00. The firm has a market cap of $1,569.11, a P/E ratio of 17.30 and a beta of 1.07.
USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings data on Tuesday, October 24th. The company reported $1.02 EPS for the quarter, beating the Zacks’ consensus estimate of $0.91 by $0.11. The company had revenue of $261.77 million for the quarter, compared to the consensus estimate of $259.52 million. USANA Health Sciences had a net margin of 8.79% and a return on equity of 26.38%. The company’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.40 EPS. analysts predict that USANA Health Sciences, Inc. will post 3.7 EPS for the current year.
USANA Health Sciences announced that its Board of Directors has approved a share repurchase program on Tuesday, July 25th that permits the company to buyback $64.60 million in shares. This buyback authorization permits the company to purchase up to 46% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s board of directors believes its stock is undervalued.
About USANA Health Sciences
USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia.
Receive News & Ratings for USANA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.